Hyperkalemia - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the drug development landscape of the drug development for hyperkalemia including molecules at pre-clinical and other discovery stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as indication coverage, therapies employed, types of molecular used, mechanism of action, and preferred route of administration.

Overview of the drug development pipeline for hyperkalemia

Hyperkalemia is a medical condition in which the level of potassium in the blood stream increases and is categorized into mild hyperkalemia, moderate hyperkalemia, and severe hyperkalemia. Severe hyperkalemia can result in cardiac attest and lead to death. Palpitations, numbness, muscle pain, muscle weakness, nausea are some of the symptoms in patients suffering from severe hyperkalemia. Factors such as dehydration, chronic kidney disease (CKD), and type 1 diabetes are some of the main causes of hyperkalemia. Technavio’s market research analysts have predicted that with the introduction of diuretics, alkalinizing agents, and dialysis as some of the most promising approaches to treat hyperkalemia, the global hyperkalemia market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under phase III stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperkalemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Ardelyx
• AstraZeneca
• CytoSorbents

Therapeutic assessment of the drug development pipeline for hyperkalemia by indication coverage

• Hyperkalemia
• Severe hyperkalemia

The hyperkalemia therapeutic assessment involves the development of majority of drugs for hyperkalemia in comparison to severe therapeutic assessment. Hyperkalemia can be controlled by medications.

Therapeutic assessment of the drug development pipeline for hyperkalemia by mechanism of action

• Potassium secretagogue
• Potassium binder

According to this pipeline analysis report, some of the molecules that are currently in the drug development pipeline for hyperkalemia are being developed for the potassium binder mechanism of action. Potassium binder are administered orally or by retention enema for hyperkalemia.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for hyperkalemia?
• What are the companies that are currently involved in the development of drug development molecules for hyperkalemia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.